Could you give us an overview of Bone Therapeutics?
At Bone Therapeutics we develop highly innovative products for patients with high unmet medical needs in the areas of orthopedics and inflammation.
Our lead product, JTA-004 is a novel and highly differentiated product, currently in Phase III clinical trials for knee osteoarthritis. This is an indication where patients are clearly underserved by current treatments. We have so far seen extremely encouraging results in previous trials and as a result we feel confident that JTA-004 can make a real difference to those patients.
Our allogeneic (donor-derived), off-the-shelf, stem cell platform is our major focus and a significant value driver for the company. The first product from this platform is ALLOB, which is about to commence a Phase 2b clinical trial. We are continuing to build on this innovative platform to develop new differentiated products for more indications where patients have limited options available to them, such as inflammation, always with a focus on efficacy and safety.
We are building partnerships with companies that can help us accelerate our route to market and are always on the look for new technologies that can help us remain at the cutting edge of innovation.
How is ALLOB different from existing therapies?
Stem cell therapies and the field of regenerative medicine have been exponentially growing in recent years. Our mission is to be one of the leading companies in the field, by developing products tailored to the specific features of each indication we treat.
This story is from the November 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the November 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.
